DrugBank 5.0: a major update to the DrugBank database for 2018
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
DrugBank (www.drugbank.ca) is a web-enabled database containing comprehensive molecular information about drugs, their mechanisms, their interactions and their targets. First described in 2006, DrugBank has continued to evolve over the past 12 years in response to marked improvements to web standards and changing needs for drug research and development. This year's update, DrugBank 5.0, represents the most significant upgrade to the database in more than 10 years. In many cases, existing data content has grown by 100% or more over the last update. For instance, the total number of investigational drugs in the database has grown by almost 300%, the number of drug-drug interactions has grown by nearly 600% and the number of SNP-associated drug effects has grown more than 3000%. Significant improvements have been made to the quantity, quality and consistency of drug indications, drug binding data as well as drug-drug and drug-food interactions. A great deal of brand new data have also been added to DrugBank 5.0. This includes information on the influence of hundreds of drugs on metabolite levels (pharmacometabolomics), gene expression levels (pharmacotranscriptomics) and protein expression levels (pharmacoprotoemics). New data have also been added on the status of hundreds of new drug clinical trials and existing drug repurposing trials. Many other important improvements in the content, interface and performance of the DrugBank website have been made and these should greatly enhance its ease of use, utility and potential applications in many areas of pharmacological research, pharmaceutical science and drug education.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“DrugBank primarily contains drug indications extracted from drug labels, while MEDI utilizes public internet sources to drug indications, and is a well utilized resource of drug indications.”
From OnSIDES database: Extracting adverse drug events from drug labels using natural language processing models (2025) · cites this paper as [48]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Finally, we searched DrugBank84 to identify therapeutic compounds targeting AD-associated proteins. Of the 38 proteins, 15 had reported molecules (Fig. 4D).”
From Proteogenomic analysis of human cerebrospinal fluid identifies neurologically relevant regulation and implicates causal proteins for Alzheimer’s disease (2024) · cites this paper as [84]
In the citing paper
“AVPR2 and NPR1 genes play pivotal roles in regulating fluid and electrolyte balance via complementary but distinct pathways. AVPR2 contributes to water retention and urine concentration, whereas NPR1 facilitates vasodilatation, lowers blood pressure and enhances water excretion47.”
From A foundation model for clinician-centered drug repurposing (2024) · cites this paper as [47]
In the citing paper
“In essence, the CC is an alternative representation of the small-molecule knowledge deposited in the public domain and, as such, it is also limited by the availability of experimental data and the coverage of its source databases (e.g., ChEMBL9 or DrugBank10).”
From Bioactivity descriptors for uncharacterized chemical compounds (2021) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892 · cited 1×
“DrugBank 1.0, released in 2006, provided novel (at the time) physico-chemical data on selected FDA-approved drugs and their drug-targets (2).”
BackgroundInfluentialSelf-citationDrugBank: a knowledgebase for drugs, drug actions and drug targets
Wishart, D. S., Knox, C., Guo, A. C., Cheng, D., Shrivastava, S., Tzur, D., Gautam, B., & Hassanali, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm958 · Cited by 2,861 · cited 1×
“DrugBank 2.0, released in 2008, added pharmacological, pharmacogenomic and molecular biological data (3).”
BackgroundInfluentialSelf-citationThe new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog)
MacArthur, J., Bowler, E., Cerezo, M., Gil, L., Hall, P., Hastings, E., Junkins, H., McMahon, A., Milano, A., Morales, J., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1133 · Cited by 2,161 · cited 2×
“org and FDA labels), as well as material collated from sources such as The Human Cytochrome P450 (CYP) Allele Nomenclature Database (12) and the NHGRI-EBI GWAS Catalog (13).”
BackgroundDrugBank 4.0: shedding new light on drug metabolism
Law, V., Knox, C., Djoumbou, Y., Jewison, T., Guo, A. C., Liu, Y., Maciejewski, A., Arndt, D., Wilson, M., Neveu, V., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1068 · Cited by 1,993 · cited 1×
“tion, distribution, metabolism, excretion and toxicity) data (5).”
Self-citationDrugBank 3.0: a comprehensive resource for 'Omics' research on drugs
Knox, C., Law, V., Jewison, T., Liu, P., Ly, S., Frolkis, A., Pon, A., Banco, K., Mak, C., Neveu, V., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1126 · Cited by 1,831 · cited 1×
“DrugBank 3.0, released in 2010, added drug–drug and drug–food interactions, drug transporter data as well as pharmacokinetic information (4).”
BackgroundInfluentialSelf-citationClassyFire: automated chemical classification with a comprehensive, computable taxonomy
Djoumbou Feunang, Y., Eisner, R., Knox, C., Chepelev, L., Hastings, J., Owen, G., Fahy, E., Steinbeck, C., Subramanian, S., Bolton, E., et al. (2016) · Journal of Cheminformatics · doi:10.1186/s13321-016-0174-y · Cited by 1,525
Self-citationThe Comparative Toxicogenomics Database: update 2017
Davis, A. P., Grondin, C. J., Johnson, R. J., Sciaky, D., King, B. L., McMorran, R., Wiegers, J., Wiegers, T. C., & Mattingly, C. J. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw838 · Cited by 544 · cited 1×
“Additional pharmacoproteomic and pharmacotranscriptomic data were obtained from the CTD (18).”
MethodPredicting drug metabolism: experiment and/or computation?
Kirchmair, J., Göller, A. H., Lang, D., Kunze, J., Testa, B., Wilson, I. D., Glen, R. C., & Schneider, G. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4581 · Cited by 502 · cited 1×
“It has also become much more robust and sophisticated (21).”
BackgroundAllen, F., Pon, A., Wilson, M., Greiner, R., & Wishart, D. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku436 · Cited by 464 · cited 7×
“In particular, CFM-ID (19) and CFM-ID 2.”
BackgroundInfluentialSelf-citationSim, S. C., & Ingelman-Sundberg, M. (2010) · Human Genomics · doi:10.1186/1479-7364-4-4-278 · Cited by 216 · cited 2×
“org and FDA labels), as well as material collated from sources such as The Human Cytochrome P450 (CYP) Allele Nomenclature Database (12) and the NHGRI-EBI GWAS Catalog (13).”
Background
Cited by
Items 601–700 of 1,056
Intense bitterness of molecules: Machine learning for expediting drug discovery
Margulis, E., Dagan‐Wiener, A., Ives, R. S., Jaffari, S., Siems, K., & Niv, M. Y. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.12.030 · Cited by 79
“The use of sophisticated and highly automated processes in drug discovery has resulted in expedited pipelines and the approval of more than 4,000 medicines as of April 2020 [1].”
BackgroundMahmud, S., Chen, W., Liu, Y., Awal, M. A., Ahmed, K., Rahman, M. H., & Moni, M. A. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab046 · Cited by 76
Self-citationWang, S., Du, Z., Ding, M., Rodríguez‐Patón, A., & Song, T. (2021) · Applied Intelligence · doi:10.1007/s10489-021-02454-8 · Cited by 75
Machine Learning in Antibacterial Drug Design
Jukič, M., & Bren, U. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.864412 · Cited by 88
“The team then constructed a predictor for antibacterial agents based on all three models and applied it to the FDA-approved small-molecule database (DrugBank, Wishart et al., 2018).”
BackgroundMethodDRESIS: the first comprehensive landscape of drug resistance information
Sun, X., Zhang, Y., Li, H., Zhou, Y., Shi, S., Chen, Z., He, X., Zhang, H., Li, F., Yin, J., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac812 · Cited by 82
TCMIO: A Comprehensive Database of Traditional Chinese Medicine on Immuno-Oncology
Liu, Z., Cai, C., Du, J., Liu, B., Cui, L., Fan, X., Wu, Q., Fang, J., & Xie, L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00439 · Cited by 90
“Drug information for targets can be accessed through a DrugBank (Wishart et al., 2018) link.”
BackgroundPROTAC Cell Permeability and Oral Bioavailability: A Journey Into Uncharted Territory
Poongavanam, V., & Kihlberg, J. (2022) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0208 · Cited by 72
Single-Cell Techniques and Deep Learning in Predicting Drug Response
Wu, Z., Lawrence, P. J., Ma, A., Zhu, J., Xu, D., & Ma, Q. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.10.004 · Cited by 79
“For example, DeepDTIs employed a Deep Belief Network ( DBN ) model to extract features from drug-target data in the DrugBank database [16] and predicted the interaction likelihood of drug-target pairs [17].”
Evans, S. E., Harrington, T. S., Rodríguez-Rivero, M. C., Rognin, E., Tuladhar, T. R., & Daly, R. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120443 · Cited by 76
Uncovering genetic mechanisms of hypertension through multi-omic analysis of the kidney
Eales, J., Jiang, X., Xu, X., Saluja, S., Akbarov, A., Cano-Gamez, E., McNulty, M. T., Finan, C., Guo, H., Wystrychowski, W., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00835-w · Cited by 76
From pharmacogenetics to pharmaco-omics: Milestones and future directions
Auwerx, C., Sadler, M. C., Reymond, A., & Kutalik, Z. (2022) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2022.100100 · Cited by 90
Generation of 3D molecules in pockets via a language model
Feng, W., Wang, L., Lin, Z., Zhu, Y., Wang, H., Dong, J., Bai, R., Wang, H., Zhou, J., Peng, W., et al. (2024) · Nature Machine Intelligence · doi:10.1038/s42256-023-00775-6 · Cited by 106
“To define the drug-like region, we considered a QED value of 0.3 or higher and a SAS value of 5 or lower, which encompass more than 80% of the molecules in DrugBank 37 .”
InfluentialYang, Z., Zeng, X., & Tsui, S. K. (2019) · BMC Genomics · doi:10.1186/s12864-019-5746-6 · Cited by 83
“The shortlisted proteins were then searched against chEMBL [43] and Drugbank [44] database to find if any suitable drug were present for this target.”
A network-based approach to identify deregulated pathways and drug effects in metabolic syndrome
Misselbeck, K., Parolo, S., Lorenzini, F., Savoca, V., Leonardelli, L., Bora, P., Morine, M. J., Mione, M., Domenici, E., & Priami, C. (2019) · Nature Communications · doi:10.1038/s41467-019-13208-z · Cited by 75
XAI-based Clinical Decision Support System: A Systematic Review
Kim, S., Kim, D., Kim, M., Ko, H., & Jeong, O. (2024) · doi:10.20944/preprints202406.0721.v1 · Cited by 72
Systems Biology Analysis Reveals Eight SLC22 Transporter Subgroups, Including OATs, OCTs, and OCTNs
Engelhart, D. C., Granados, J. C., Shi, D., Saier, M. H., Baker, M. E., Abagyan, R. A., & Nigám, S. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051791 · Cited by 77
“To determine the diversity of substrate specificity, the number of drugs that list SLC22 members as a target on DrugBank were recorded [22].”
BackgroundKim, S., Cheng, T., He, S., Thiessen, P. A., Li, Q., Gindulyte, A., & Bolton, E. E. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167514 · Cited by 67
Artificial Intelligence: The Milestone in Modern Biomedical Research
Athanasopoulou, K., Daneva, G. N., Adamopoulos, P. G., & Scorilas, A. (2022) · BioMedInformatics · doi:10.3390/biomedinformatics2040049 · Cited by 92
Beyond the Flavour: The Potential Druggability of Chemosensory G Protein-Coupled Receptors
Pizio, A. D., Behrens, M., & Krautwurst, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061402 · Cited by 77
“DrugBank is a freely accessible database containing information on approved drugs and drug candidates [147,148].”
BackgroundCannabinoids: Current and Future Options to Treat Chronic and Chemotherapy-Induced Neuropathic Pain
Blanton, H. L., Brelsfoard, J., Deturk, N., Pruitt, K., Narasimhan, M., Morgan, D. J., & Guindon, J. (2019) · Drugs · doi:10.1007/s40265-019-01132-x · Cited by 77
HyperFoods: Machine intelligent mapping of cancer-beating molecules in foods
Veselkov, K., Gonzalez, G., Aljifri, S., Galea, D., Mirnezami, R., Youssef, J., Bronstein, M., & Laponogov, I. (2019) · Scientific Reports · doi:10.1038/s41598-019-45349-y · Cited by 71
DTi2Vec: Drug–target interaction prediction using network embedding and ensemble learning
Thafar, M. A., Olayan, R. S., Albaradei, S., Bajic, V. B., Gojobori, T., Essack, M., & Gao, X. (2021) · Journal of Cheminformatics · doi:10.1186/s13321-021-00552-w · Cited by 70
Drug repurposing using computational methods to identify therapeutic options for COVID-19
Mahdian, S., Ebrahim‐Habibi, A., & Zarrabi, M. (2020) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-020-00546-9 · Cited by 70
“The section of small-molecules of the Drug Bank database [15] (https://www.drugbank.ca/about) was used to obtain all FDA-approved drugs.”
MethodTakaya, D., Watanabe, C., Nagase, S., Kamisaka, K., Okiyama, Y., Moriwaki, H., Yuki, H., Sato, T., Kurita, N., Yagi, Y., et al. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c01062 · Cited by 76
Application of Machine Learning for Drug–Target Interaction Prediction
Xu, L., Ru, X., & Song, R. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.680117 · Cited by 80
“DrugBank database3: As a bioinformatics and cheminformatics resource, DrugBank combines detailed drug data (i.e., chemical, pharmacological, and pharmaceutical) with comprehensive target information (i.e., sequence, structure, and pathway) (Wishart et al., 2018).”
BackgroundThe Multifaceted Roles of Mast Cells in Immune Homeostasis, Infections and Cancers
Sobiepanek, A., Kuryk, Ł., Garofalo, M., Kumar, S., Baran, J., Musolf, P., Siebenhaar, F., Fluhr, J. W., Kobiela, T., Plasenzotti, R., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042249 · Cited by 74
Shirai, Y., Nakanishi, Y., Suzuki, A., Konaka, H., Nishikawa, R., Sonehara, K., Namba, S., Tanaka, H., Masuda, T., Yaga, M., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2022-222460 · Cited by 74
“By querying them through Drug-Bank 41 and TTD, 42 we found that CXCR4 and its functionally related genes have been therapeutic targets of various autoimmune and allergic diseases (online supplemental figure 11B).”
Fu, S., Zhou, Y., Hu, C., Xu, Z., & Hou, J. (2022) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-022-03662-6 · Cited by 75
“ca/) is a comprehensive bioinformatics and cheminformatics database that provides detailed information on drug types, chemical structures, drug targets and other information [23].”
BackgroundLv, Q., Chen, G., He, H., Yang, Z., Zhao, L., Chen, H., & Chen, C. Y. (2023) · Chemical Science · doi:10.1039/d3sc02139d · Cited by 73
ZeroBind: a protein-specific zero-shot predictor with subgraph matching for drug-target interactions
Wang, Y., Xia, Y., Yan, J., Yuan, Y., Shen, H., & Pan, X. (2023) · Nature Communications · doi:10.1038/s41467-023-43597-1 · Cited by 80
“Data-driven learning methods generally formulate drug-target interaction (DTI) prediction as binary classi fi cation or regression tasks 8 – 11 , where interacting pairs of proteins and drugs are extracted from existing databases like BindingDB 12 , CHEMBL 13 , PDBbind 14,15 , and DrugBank 16 .”
A Division of Labor between YAP and TAZ in Non–Small Cell Lung Cancer
Shreberk-Shaked, M., Dassa, B., Sinha, S., Di Agostino, S., Azuri, I., Mukherjee, S., Aylon, Y., Blandino, G., Ruppin, E., & Oren, M. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0125 · Cited by 67
“Then, by usingDrugbank (34) annotation, the targets for each of the YAP-differential or TAZ-differential drugs were defined.”
MethodCurcumin Inhibits the Primary Nucleation of Amyloid-Beta Peptide: A Molecular Dynamics Study
Doytchinova, I. A., Atanasova, M., Salamanova, E., Ivanov, S. M., & Dimitrov, I. (2020) · Biomolecules · doi:10.3390/biom10091323 · Cited by 73
“The linker length is 12 Å. FA contains only one aromatic ring and is a weaker inhibitor of Aβ aggregation than CU. a Calculated by ACD/Labs (ACD/ChemSketch, version 2020.1.0); b PubChem [44]; c [31]; d [43]; e DrugBank [71]; f [68]; g [72].”
InfluentialQuantum computing at the quantum advantage threshold: a down-to-business reviewPreprint
Fedorov, A. K., Gisin, N., Beloussov, S. M., & Lvovsky, A. I. (2022) · arXiv (Cornell University) · doi:10.48550/arxiv.2203.17181 · Cited by 104
“0 [381] have molecular weights between up to 1800 atomic mass units [82, 382].”
BackgroundHe, K., Mao, R., Lin, Q., Ruan, Y., Lan, X., Feng, M., & Cambria, E. (2024) · doi:10.2139/ssrn.4809363 · Cited by 69
Nowakowska, K., Giebułtowicz, J., Kamaszewski, M., Adamski, A., Szudrowicz, H., Ostaszewska, T., Solarska-Dzięciołowska, U., Nałęcz‐Jawecki, G., Wroczyński, P., & Drobniewska, A. (2019) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/j.cbpc.2019.108670 · Cited by 69
Pharmacoinformatic Investigation of Medicinal Plants from East Africa
Simoben, C. V., Qaseem, A., Moumbock, A. F. A., Telukunta, K. K., Günther, S., Sippl, W., & Ntie‐Kang, F. (2020) · Molecular Informatics · doi:10.1002/minf.202000163 · Cited by 75
Assress, H. A., Selvarajan, R., Nyoni, H. H., Mamba, B. B., & Msagati, T. A. M. (2021) · Reviews in Environmental Science and Bio/Technology · doi:10.1007/s11157-021-09594-w · Cited by 73
“Studies have observed that long-term unstable and warming weather conditions are playing an increasing role in reviving, redistribution and the global emergence of various infectious diseases (Wu et al. 2016).”
BackgroundCell Taxonomy: a curated repository of cell types with multifaceted characterization
Jiang, S., Qian, Q., Zhu, T., Zong, W., Shang, Y., Jin, T., Zhang, Y., Chen, M., Wu, Z., Chu, Y., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac816 · Cited by 76
“In addition, 1,899 human cell markers are targeted by approved drugs listed in DrugBank (46), which are mostly inhibitor targets (876) and antagonist targets (288) (Figure 2B).”
BackgroundCalabon, M. S., Hyde, K., Jones, E., Bao, D., Bhunjun, C. S., Phukhamsakda, C., Shen, H. F., Gentekaki, E., Sharie, A. A., de Barros, J. S., et al. (2023) · Mycosphere · doi:10.5943/mycosphere/14/1/4 · Cited by 91
Orphan Drugs and Their Impact on Pharmaceutical Development
Attwood, M. M., Rask‐Andersen, M., & Schiöth, H. B. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.03.003 · Cited by 75
Douglass, E. F., Allaway, R. J., Szalai, B., Wang, W., Tian, T., Fernández-Torras, A., Realubit, R., Karan, C., Zheng, S., Pessia, A., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100492 · Cited by 68
ROBOKOP KG and KGB: Integrated Knowledge Graphs from Federated Sources
Bizon, C., Cox, S., Balhoff, J. P., Kebede, Y., Wang, P., Morton, K. D., Fecho, K., & Tropsha, A. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00683 · Cited by 77
Ji, B., You, Z., Cheng, L., Zhou, J.-R., Alghazzawi, D., & Li, L.-P. (2020) · Scientific Reports · doi:10.1038/s41598-020-63735-9 · Cited by 70
Chen, Z., You, Z., Guo, Z.-H., Yi, H.-C., Luo, G., & Wang, Y. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00338 · Cited by 69
Targeting SARS-COV-2 non-structural protein 16: a virtual drug repurposing study
Tazikeh-Lemeski, E., Moradi, S., Raoufi, R., Shahlaei, M., Janlou, M. A. M., & Zolghadri, S. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1779133 · Cited by 71
“The SwissSimilarity (http://www.swisssimilarity.ch/) (Zoete et al., 2016) and drug bank (https://www.drugbank.ca/ ) (Wishart et al., 2017), two online platforms, were used to identify and screen some chemical hits from FDA approved drugs library with respect to SAM and sinefungin as reference…”
MethodColuzzi, F., Caputi, F. F., Billeci, D., Pastore, A. L., Candeletti, S., Rocco, M., & Romualdi, P. (2020) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s262843 · Cited by 75
In silico identification of Tretinoin as a SARS-CoV-2 envelope (E) protein ion channel inhibitor
Dey, D., Borkotoky, S., & Banerjee, M. (2020) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2020.104063 · Cited by 71
Shoily, S. S., Ahsan, T., Fatema, K., & Sajib, A. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-86801-2 · Cited by 74
3DGT-DDI: 3D graph and text based neural network for drug–drug interaction prediction
He, H., Chen, G., & Chen, C. Y. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac134 · Cited by 79
Wang, H., Huang, F. F., Xiong, Z., & Zhang, W. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac184 · Cited by 75
“Additionally, for all drug entities and protein entities in the drug-protein interaction network, we collected SMILES of drugs from Drugbank(Wishart et al. , 2018) and sequences of proteins from Uniprot(Consortium, 2019).”
MethodZhang, S., Yan, Z., Huang, Y., Liu, L., He, D., Wang, W., Fang, X., Zhang, X., Wang, F., Wu, H., et al. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac342 · Cited by 60
“Labelled Data: The labelled data for ADMET and physicochemical endpoints and the auxiliary tasks was collected from various data sources, including DrugBank (31), ChEMBL (32), CPDB (33), PubChem assays (34), peer-reviewed scientific papers (35–41), and high-throughput screening projects such as Tox21 Data Challenge 20…”
MethodInfluentialTang, B., Wang, Y., Jiang, X., Thambisetty, M., Ferrucci, L., Johnell, K., & Hägg, S. (2022) · Neurology · doi:10.1212/wnl.0000000000200771 · Cited by 76
“Information regarding the pharmacologically active protein targets and corresponding encoding genes was retrieved from the DrugBank and the ChEMBL databases separately (Table 1).(17,18) Because the protein targets of metformin differed in the 2 databases and the molecules underlying metformin’s physiologic effects rem…”
Improved prediction of drug-drug interactions using ensemble deep neural networks
Vo, T. H., Nguyen, N. T. K., & Le, N. Q. K. (2022) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2022.100149 · Cited by 69
Lu, S., Sun, X., Zhou, Z., Tang, H., Xiao, R., Lv, Q., Wang, B., Qu, J., Yu, J., Sun, F., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1235575 · Cited by 72
“com/) (36), GeneCards (https://genecards.”
Self-citationExploring the chemical space of orally bioavailable PROTACs
Apprato, G., Poongavanam, V., Jiménez, D. G., Atilaw, Y., Erdélyi, M., Ermondi, G., Caron, G., & Kihlberg, J. O. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.103917 · Cited by 79
A review of deep learning methods for ligand based drug virtual screening
Wu, H., Liu, J., Zhang, R., Lu, Y., Cui, G., Cui, Z., & Ding, Y. (2024) · Fundamental Research · doi:10.1016/j.fmre.2024.02.011 · Cited by 76
“DrugBank is one of the most widely used databases and has become a reliable resource for drug reference information [39] .”
BackgroundMethodInfluentialStructural Analysis and Identification of Colloidal Aggregators in Drug Discovery
Yang, Z., Yang, Z., Dong, J. N., Wang, L., Zhang, L., Ding, J., Ding, X., Lü, A., Hou, T., & Cao, D. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00541 · Cited by 68
Drug Repurposing Using Deep Embeddings of Gene Expression Profiles
Donner, Y., Kazmierczak, S., & Fortney, K. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00284 · Cited by 73
GREP: genome for REPositioning drugs
Sakaue, S., & Okada, Y. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz166 · Cited by 70
Genomics functional analysis and drug screening of SARS-CoV-2
Chen, L., & Li, Z. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.04.002 · Cited by 70
Nose-to-brain delivery of antipsychotics using nanotechnology: a review
Tan, M. S. A., Parekh, H. S., Pandey, P. M., Siskind, D. J., & Falconer, J. R. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1762563 · Cited by 72
“Table 5 summarizes the nanoparticles loaded with commonly used SGAs for in vivo studies.”
InfluentialArtigas, L., Coma, M., Matos‐Filipe, P., Aguirre‐Plans, J., Farrés, J., Valls, R., Fernández‐Fuentes, N., de la Haba-Rodríguez, J., Olvera, À., Barberá, J. M., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240149 · Cited by 75
Current Challenges and Opportunities in Designing Protein–Protein Interaction Targeted Drugs
Shin, W.-H., Kumazawa, K., Imai, K., Hirokawa, T., & Kihara, D. (2020) · Advances and Applications in Bioinformatics and Chemistry · doi:10.2147/aabc.s235542 · Cited by 64
Molavi, Z., Razi, S., Mirmotalebisohi, S. A., Adibi, A., Sameni, M., Karami, F., Niazi, V., Niknam, Z., Aliashrafi, M., Taheri, M., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111544 · Cited by 74
CYPlebrity: Machine learning models for the prediction of inhibitors of cytochrome P450 enzymes
Płonka, W., Stork, C., Šícho, M., & Kirchmair, J. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116388 · Cited by 69
Recent applications of quantitative systems pharmacology and machine learning models across diseases
Aghamiri, S. S., Amin, R., & Helikar, T. (2021) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-021-09790-9 · Cited by 71
“Using the DrugBank database, the PMF model was trained by 14,983 interactions between 5,494 drugs and 2,807 targets.”
MethodInfluentialMDDI-SCL: predicting multi-type drug-drug interactions via supervised contrastive learning
Lin, S., Chen, W., Chen, G., Zhou, S., Wei, D., & Xiong, Y. (2022) · Journal of Cheminformatics · doi:10.1186/s13321-022-00659-8 · Cited by 73
He, H., Chen, G., & Chen, C. Y. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad355 · Cited by 67
“The DrugBank database (Wishart et al. 2018) was used to obtain 2509 FDA-approved drugs as potential inhibitors waiting for screening.”
Wang, B., Yang, C., Jin, X., Du, Q., Wu, H., Dall’Acqua, W. F., & Mazor, Y. (2019) · mAbs · doi:10.1080/19420862.2019.1690959 · Cited by 72
Phenotyping Reveals Targets of a Pseudo‐Natural‐Product Autophagy Inhibitor
Foley, D. J., Zinken, S., Corkery, D., Laraia, L., Pahl, A., Wu, Y., & Waldmann, H. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202000364 · Cited by 74
Li, R., Wu, K., Yu, L., Xiao, L., Lai, K. P., & Chen, J. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa141 · Cited by 73
“Potential targets were acquired after a thorough analysis of the Traditional Chinese Medicine Systems Pharmacology (TCMSP) [23], Drugbank [24], SuperPred, Swiss Target Prediction [25], ChemMapper [26], Bioinformatics Analysis Tool for Molecular mechANism of Traditional Chinese Medicine (BATMAN TCM) [27] and SuperPred…”
MethodStructure prediction of cyclic peptides by molecular dynamics + machine learning
Miao, J., Descoteaux, M. L., & Lin, Y.-S. (2021) · Chemical Science · doi:10.1039/d1sc05562c · Cited by 69
Molecular Modeling Strategies of Cancer Multidrug Resistance
Yalçın, G. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100789 · Cited by 66
Artificial intelligence in clinical research of cancers
Shao, D., Dai, Y., Li, N., Cao, X., Zhao, W., Li, C., Rong, Z., Huang, L., Wang, Y., & Zhao, J. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab523 · Cited by 71
“Existing resource to facilitate the cancer drug discovery include DepMap [62], Genomics of Drug Sensitivity in Cancer (GDSC) [63], canSAR [64], Open Targets [65], TG-GATE [66], drugBank [67] and others.”
Self-citationBo, W., Qin, D., Zheng, X., Wang, Y., Ding, B., Li, Y., & Liang, G. (2022) · Food Research International · doi:10.1016/j.foodres.2022.110974 · Cited by 72
Tognetti, M., Sklodowski, K., Müller, S., Kamber, D., Muntel, J., Bruderer, R., & Reiter, L. (2022) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00122 · Cited by 70
Ahmed, F., Lee, J. W., Samantasinghar, A., Kim, Y. S., Kim, K. H., Kang, I. S., Memon, F. H., Lim, J. H., & Choi, K. H. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.902123 · Cited by 65
“Moreover, a study using the deep learning model (73) conducted pre-training on the interactions, and MT-DTI identified the EGFR receptor successfully as the drug–target that has been associated with 30 candidates out of 1,094 from the DrugBank.”
MethodInfluentialOccurrence, hazard, and risk of psychopharmaceuticals and illicit drugs in European surface waters
Davey, C. J. E., Kraak, M. H. S., Praetorius, A., ter Laak, T. L., & van Wezel, A. P. (2022) · Water Research · doi:10.1016/j.watres.2022.118878 · Cited by 69
“CAS numbers were obtained from DrugBank and Pub-Chem (Kim et al., 2021; Wishart et al., 2018).”
MethodA computational approach to drug repurposing using graph neural networks
Doshi, S., & Chepuri, S. P. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105992 · Cited by 79
A practical guideline of genomics-driven drug discovery in the era of global biobank meta-analysis
Namba, S., Konuma, T., Wu, K.-H., Zhou, W., Initiative, G. B. M.-A., & Okada, Y. (2022) · Cell Genomics · doi:10.1016/j.xgen.2022.100190 · Cited by 75
Predicting Drug-Target Interactions Over Heterogeneous Information Network
Su, X., Hu, P., Yi, H.-C., You, Z., & Hu, L. (2022) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2022.3219213 · Cited by 70
Xu, F., Yu, E. Y.-W., Cai, X., Yue, L., Jing, L.-P., Liang, X., Fu, Y., Miao, Z., Yang, M., Shuai, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36491-3 · Cited by 69
Alonso, E., Sanchez-Huerta, C., Ali, Z., Wang, Y., Fortunato, L., & Pinnau, I. (2023) · Journal of Membrane Science · doi:10.1016/j.memsci.2023.122357 · Cited by 69
BO-LSTM: classifying relations via long short-term memory networks along biomedical ontologies
Lamúrias, A., Sousa, D., Clarke, L. A., & Couto, F. M. (2019) · BMC Bioinformatics · doi:10.1186/s12859-018-2584-5 · Cited by 74
Konings, G. F. J., Brentjens, L. S., Delvoux, B., Linnanen, T., Cornel, K. M. C., Koskimies, P., Bongers, M. Y., Kruitwagen, R. F. P. M., Xanthoulea, S., & Romano, A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00940 · Cited by 76
Roy, G., Galigama, R. D., Thorat, V. S., Garg, P., & Venuganti, V. V. K. (2020) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2020.1776317 · Cited by 69
Ibrahim, M. A. A., Abdelrahman, A. H. M., Allemailem, K. S., Almatroudi, A., Moustafa, M., & Hegazy, M. F. (2021) · The Protein Journal · doi:10.1007/s10930-020-09945-6 · Cited by 65
Fu, D., Zhang, B., Wu, S., Zhang, M. Y., Xie, J., Ning, W., & Jiang, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.695865 · Cited by 72
Node similarity-based graph convolution for link prediction in biological networks
Coşkun, M., & Koyutürk, M. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btab464 · Cited by 75
DeepCarc: Deep Learning-Powered Carcinogenicity Prediction Using Model-Level Representation
Li, T., Tong, W., Roberts, R. A., Liu, Z., & Thakkar, S. (2021) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2021.757780 · Cited by 67
“First, we collected 10,741 compounds from DrugBank database version 5.1.7 (Wishart et al., 2018), including approved and investigational drugs.”
MethodInfluentialIn Silico ADME Profiling of Salubrinal and Its Analogues
Zadorozhnii, P. V., Kiselev, V. V., & Kharchenko, A. V. (2022) · Future Pharmacology · doi:10.3390/futurepharmacol2020013 · Cited by 74
Tripathi, S., Augustin, A. I., Dunlop, A., Sukumaran, R., Dheer, S., Zavalny, A., Haslam, O., Austin, T., Donchez, J., Tripathi, P. K., et al. (2022) · Artificial Intelligence in the Life Sciences · doi:10.1016/j.ailsci.2022.100045 · Cited by 59
Formal Cross-Coupling of Amines and Carboxylic Acids to Form sp 3 –sp 2 Carbon–Carbon Bonds
Douthwaite, J. L., Zhao, R., Shim, E., Mahjour, B. A., Zimmerman, P. M., & Cernak, T. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c11563 · Cited by 65
The genetic architecture of multimodal human brain age
Wen, J., Zhao, B., Yang, Z., Erus, G., Skampardoni, I., Mamourian, E., Cui, Y., Hwang, G., Bao, J., Boquet-Pujadas, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46796-6 · Cited by 74
Learning motif-based graphs for drug–drug interaction prediction via local–global self-attention
Zhong, Y., Li, G., Ji, Y., Zheng, H., Yu, Y., Zhang, J., Luo, H., Wang, B., & Weng, Z. (2024) · Nature Machine Intelligence · doi:10.1038/s42256-024-00888-6 · Cited by 83
“Note that only one description is given to a metabolic DDI in DrugBank.”
InfluentialLiu, J., Nile, S. H., Xu, G., Wang, Y., & Kai, G. (2019) · Phytomedicine · doi:10.1016/j.phymed.2019.153077 · Cited by 68
DRIMC: an improved drug repositioning approach using Bayesian inductive matrix completion
Zhang, W., Xu, H., Li, X., Gao, Q., & Wang, L. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa062 · Cited by 66
Rodrigues, L., Cravo, P., & Viveiros, M. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1760845 · Cited by 71
Meyer, C., Stravs, M. A., & Hollender, J. (2024) · Environmental Science & Technology · doi:10.1021/acs.est.4c00968 · Cited by 64
A review on the recent applications of deep learning in predictive drug toxicological studies
Sinha, K., Ghosh, N., & Sil, P. C. (2023) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.2c00375 · Cited by 64
Metadata
- Authors
- Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., Assempour, N., Iynkkaran, I., Liu, Y., Maciejewski, A., Gale, N., Wilson, A., Chin, L., Cummings, R., Le, D., Pon, A., Knox, C., & Wilson, M.
- Affiliations
- University of Alberta (CA)
- Corresponding author
- Wishart, David S
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-11-08
- Volume
- 46
- Issue
- D1
- Pages
- D1074-D1082
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC5753335
- OpenAlex
- W2767891136
- Cited by
- 8,404
- References
- 22
- Citations by year
- 2026: 617 · 2025: 929 · 2024: 1327 · 2023: 1363 · 2022: 1322 · 2021: 1175 · 2020: 957 · 2019: 502 · 2018: 201 · 2017: 5
- FWCI
- 343.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nucleic Acids Research (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Genome Canada
- Genome Alberta
- Health Canada
- Canadian Institutes of Health Research
- National Human Genome Research Institute
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Health Informatics › Biomedical Text Mining and Ontologies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- DrugBank, drug databases, drug-drug interactions, food-drug interactions, therapeutic target, drug mechanisms, drug indications, pharmacometabolomics, pharmacoproteomics, drug repurposing, clinical trials, investigational drugs
- MeSH terms
- Drug Interactions, User-Computer Interface, Food-Drug Interactions, Polymorphism, Single Nucleotide, Metabolome, Transcriptome, Databases, Pharmaceutical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

